Back to Portfolio

TOLREMO

Preventing resistance to cancer therapy
 
TOLREMO


Today, there is a high unmet need for durable therapeutic options for cancer patients, as current drugs often lose their effectiveness over time. Drug resistance therefore remains a major limiting factor to patient survival.

TOLREMO’s platform has the potential to generate a new wave of novel resistance-breaking therapies by targeting the resistance-causing molecular mechanisms right from the start. By combining TOLRMEO's add-on compounds with existing cancer drugs and a proprietary screening platform, the company aims to ensure that the right patient is treated with the right drug at the right time.
 


Homepage                    Twitter                      Linkedin